We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ingenuity Technology Licensed by SPRI
News

Ingenuity Technology Licensed by SPRI

Ingenuity Technology Licensed by SPRI
News

Ingenuity Technology Licensed by SPRI

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ingenuity Technology Licensed by SPRI"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ingenuity has announced that Schering-Plough Research Institute has licensed both Ingenuity Pathways Analysis and the Ingenuity Pathways Analysis Integration Module (IPA-IM).

Ingenuity Pathways Analysis 3.0 (IPA) is designed to enable biologists and bioinformaticians to model, analyze, and understand the complex biological systems at the core of all life science research.

Ingenuity claims that, IPA leverages the world largest and highest quality knowledge base of biological networks and powerful algorithms, along with a software interface, to provide researchers with the insights and confidence needed to make better and faster decisions at every step of their research.

With access to the release of Ingenuity Pathways Analysis 3.0, scientists will now be able to integrate their own biological relationships with Ingenuity pathways to create custom networks for particular targets, biomarkers, disease areas, and processes and enable powerful computation and functional analysis.

Researchers will also benefit from Ingenuity Pathways Analysis 3.0's vastly expanded search capabilities and a doubling of the gene and disease content.

Advertisement